Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: Correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices

International Journal of Gynecological Cancer

Volumn 13, Issue 3, 2003, Pages 344-351

  Ioachim, Elli ^a   Kitsiou, E ^a,b   Charalabopoulos, K ^d   Mitselou, A ^a   Zagorianakou, N ^a   Makrydimas, G ^a   Tzioras, S ^a   Salmas, M ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d NONE

Author keywords

Cathepsin D; Endometrial lesions; Hormone receptors; Immunohistochemistry

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROTEIN P53; RETINOBLASTOMA PROTEIN; NUCLEAR PROTEIN; STEROID RECEPTOR; TUMOR PROTEIN;

ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; EPITHELIUM CELL; FEMALE; GENE CONTROL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL; ADULT; BIOSYNTHESIS; CANCER STAGING; CELL TRANSFORMATION; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PRECANCER;

ADULT; CARCINOMA, ENDOMETRIOID; CATHEPSIN D; CELL TRANSFORMATION, NEOPLASTIC; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS; RECEPTORS, STEROID;

EID: 0642315317     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13181.x     Document Type: Article

References (43)

1. Liotta LA. Tumor invasion and metastases. Role of the basement membrane. Am J Pathol 1984;117:339-47.
2. Briozzo P, Morriset M, Capony F, Rougeot C, Rochefort H. In vitro degradation of extracellular matrix with Mr 52.000 Cathepsin D secreted by breast cancer cells. Cancer Res 1988;48:3688-369.
3. Briozzo P, Badet J, Capony F et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991;194:252-25.
4. Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast carcinoma cell lines. Cell 1980;20:353-62.
5. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL. Cathepsin D and prognosis in breast carcinoma. N Engl J Med 1990;322:297-302.
6. Charpin C, Devictor B, Bonnier P et al. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol 1993;170:463-70.
7. Aaltonen M, Lipponen P, Kosma VM, Aaltomaa S, Syrjanen K. Prognostic value of Cathepsin D expression in female breast carcinoma. Anticancer Res 1995;15:1033-8.
8. Schwartz MK. Tissue cathepsins as tumour markers. Clin Chim Acta 1995;237:67-8.
9. Metaye T, Millet C, Kraimps J, Aubouin B, Barbier J, Begon F. Estrogen receptors and cathepsin D in human thyroid tissue. Carcinoma 1993;72:1991-6.
10. Adenis A, Huet G, Zerimech F, Hecquet B, Balduyck M, Beyrat JP. Cathepsin B, L and D activities in colorectal carcinomas: relationship with clinico-pathological parameters. Carcinoma Lett 1995;96:267-75.
11. Maudelonde T, Martinez P, Brouillet JP, Laffargue F, Pages A, Rochefort H. Cathepsin D in human endometrium: induction by progesterone and potential value as a tumor marker. J Clin Endocrinol Metab 1990;70:115-21.
12. Nazeer T, Malfetano JH, Rosano TG, Ross JS. Correlation of tumor cytosol cathepsin D with differentiation and invasiveness of endometrial adenocarcinoma. Am J Clin Pathol 1992;97:764-9.
13. Kohler U, Langanke D, Sorger D, Martin R, Bilek K. The prognostic value of cathepsin D in endometrial carcinoma. Zentralbl Gynakol 1995;117:148-52.
14. Scambia G, Benedetti Panici P, Ferrandina G et al. Significance of Cathepsin D expression in uterine tumors. Eur J Cancer 1995;31:1449-54.
15. Nielsen AL, Nyholm HC. Endometrial adenocarcinoma of endometrioid subtype with squamous differentiation: an immunohistochemical study of MIB-1 (Ki-67 paraffin), cathepsin D, and c-erbB-2 protein (p185). Int J Gynecol Pathol 1995;14:230-4.
16. Losch A, Kohlberger P, Gitsch G, Kaider A, Breitenecker G, Kainz C. Lysosomal protease cathepsin D is a prognostic marker in endometrial cancer. Br J Cancer 1996;73:1525-8.
17. Gassel AM, Backe J, Krebs S, Schon S, Caffier H, Muller-Hermelink HK. Endometrial carcinoma. immunohistochemically detected proliferation index is a prognosticator of long-term outcome. J Clin Pathol 1998;51:25-9.
18. Inoue Y, Abe K, Obata K et al. Immunohistochemical studies concerning cathepsin D in endometrial carcinomas. J Obstet Gynaecol Res 1999;25:345-52.
19. Saygili U, Koyguncuoglu M, Altunyurt S, Guclu S, Uslu T, Erten O. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study. Gynecol Oncol 2001;83:20-4.
20. Nazeer T, Church K, Amato C et al. Comparative quantitative immunohistochemical and immunoradiometric determinations of cathepsin D in endometrial adenocarcinoma: predictors of tumor aggressiveness. Mod Pathol 1994;7:469-74.
21. FIGO stages-1988 revisions. Gynecol Oncol 1989;35:125-7.
22. Gohring UJ, Scharl A, Thelen U, Ahr A, Crombach G, Titius BR. Prognostic value of cathepsin D in breast cancer: comparison of immunohistochemical and immunoradiometric detection methods. J Clin Pathol 1996;49:57-64.
23. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS. Endometrial cancer. histologic correlates of immunohistochemical localization of progesterone and estrogen receptor. Obstet Gynecol 1989;73:780-5.
24. Sung CJ, Zheng Y, Quddus MR et al. p53 as a significant prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2000;10:119-27.
25. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 1992;31:125-30.
26. Gardieff R. Cathepsin D and breast cancer: useful? Hum Pathol 1994;25:847-8.
27. Ioachim E, Kamina S, Nonni A, Agnantis NJ. Immunohistochemical Expression of cathepsin D in correlation with extracellular matrix component, steroid receptor status and proliferative indices in breast cancer. Virchows Arch 1997;431:311-6.
28. Ioachim E, Goussia A, Machera M, Tsianos E, Kappas A, Agnantis NJ. Immunohistochemical evaluation of Cathepsin D expression in colorectal tumours. A correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. Anticancer Res 1999;19:2147-5.
29. Tetu B, Brisson J, Cote C, Brisson S, Potvin D, Roberge N. Prognostic significance of cathepsin D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer 1993;55:429-35.
30. Walker RA, Denley H, Dookeran KA. Cathepsin D in breast carcinoma. The role of the stromal cell component. Oncol Rep 1994;1:227-31.
31. Capony F, Morisset M, Barrett AJ et al. Phosphorylation glycosylation and proteolytic activity of the 52-kD estrogen-induced protein secreted by MCF7 cells. J Cell Biol 1987;104:253-62.
32. Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 1992;75:1497-502.
33. Garcia M, Lacombe MJ, Duplay H et al. Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 1987;27:439-45.
34. Elengovan S, Moulton BC. Progesterone and estrogen control of rates of synthesis of uterine Cathepsin D. J Biol Chem 1980;225:7474-9.
35. Nielsen LA, Nyholm HJC. The expression of p53 protein, c-erbB-2 protein (p185) in endometrial adenocarcinomas of endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994;102:76-9.
36. Fanning J, Brown S, Phibbs G, Kramer T, Zaher A. Immunohistochemical evaluation is not prognostic for recurrence in fully staged high-risk endometrial cancer. Int J Gynecol Cancer 2002;12:286-9.
37. Koul A, Bendahl PO, Borg A et al. TP53 protein expression analysis by luminometric immunoassay in comparison with gene mutation status and prognostic factors in early stage endometrial cancer. Int J Gynecol Cancer 2002;12:362-71.
38. Hamel NW, Sebo TJ, Wilson TO et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996;62:192-8.
39. Geisler JP, Geisler HE, Wiemann MC, Zhou Z, Miller GA, Crabtree W. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecol Oncol 1999;74:468-71.
40. Heffner HM, Freedman AN, Asirwatham JE, Lele SB. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial adenocarcinoma. Eur. J Gynecol Oncol 1999;20:8-12.
41. Lundgren C, Auer G, Frankendal B, Moberger B, Nilsson B, Nordstrom B. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002;12:110-8.
42. Hachisuga T, Fukuda K, Uchiyama M, Matsuo N, Iwasaka T, Sugimori H. Immunohistochemical study of p53 expression in endometrial carcinomas: correlation with markers of proliferating cells and clinicopathologic features. Int J Gynecol Cancer 1993;3:363-8.
43. Niemann TH, Yilmaz AG, McGaughy VR, Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1997;65:232-6.